A phase 2 single-center study of carfilzomib 56 mg/m(2) with or without low-dose dexamethasone in relapsed multiple myeloma

Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM). We report phase 2 results of carfilzomib 20 mg/m(2) on days 1 to 2 of cycle 1, 56 mg/m(2) thereafter (30-minute infusion), in R/RMM wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Lendvai, Nikoletta, Hilden, Patrick, Devlin, Sean, Landau, Heather, Hassoun, Hani, Lesokhin, Alexander M., Tsakos, Ioanna, Redling, Kaitlyn, Koehne, Guenther, Chung, David J., Schaffer, Wendy L., Giralt, Sergio A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624439/
https://ncbi.nlm.nih.gov/pubmed/24963043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-556308
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars